Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acitretin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA known ✓ | P19793 | 12/20 | 0.45 |
| ▸ | RARG known ✓ | P13631 | 9/20 | 0.45 |
| ▸ | RARA known ✓ | P10276 | 6/20 | 0.45 |
| ▸ | RARB known ✓ | P10826 | 6/20 | 0.45 |
| ▸ | RXRB known ✓ | P28702 | 4/20 | 0.45 |
| ▸ | RXRG known ✓ | P48443 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.72 |
| ▸ | PGR | P06401 | 2/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.72 |
| ▸ | ESR1 | P03372 | 1/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acitretin SCHEMBL159360 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 | |
| Acitretin SCHEMBL29883491 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 | |
| Acitretin SCHEMBL5028866 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 | |
| Acitretin SCHEMBL29496318 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 | |
| Acitretin SCHEMBL3759 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 | |
| Acitretin SCHEMBL5053805 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 | |
| Acitretin SCHEMBL10750446 | 0.99 | ALDH1A1 (0.98) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 | |
| Acitretin SCHEMBL4443721 | 0.99 | ALDH1A1 (0.98) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 | |
| Acitretin SCHEMBL9856594 | 0.94 | ALDH1A1 (0.89) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 | |
| SCHEMBL10750080 | 0.94 | ALDH1A1 (0.89) | ALDH1A1MAPTSMN1; SMN2ABCB11ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2703407-B1 | METHOD FOR MANUFACTURING PHOSPHONOCROTONIC ACID DERIVATIVE | KOWA CO (JP) | 2017-07-26 | — | — | EP | claimed |
| US-9540301-B2 | Method for manufacturing phosphonocrotonic acid derivative | KOWA COMPANY, LTD. (JP) | 2017-01-10 | — | — | US | claimed |
| US-20140249117-A1 | ACTIVE INGREDIENT COMBINATION OF A RETINOID AND A HORMONE COMBINATION WITH CONTRACEPTIVE ACTION AS MEDICAMENT FOR TREATMENT OF SKIN DISEASES | RICHTER GEDEON NYRT. (HU) | 2014-09-04 | — | — | US | claimed |
| EP-2703407-A1 | METHOD FOR MANUFACTURING PHOSPHONOCROTONIC ACID DERIVATIVE | Kowa Company, Ltd. (JP) | 2014-03-05 | — | — | EP | claimed |
| US-20140051876-A1 | METHOD FOR MANUFACTURING PHOSPHONOCROTONIC ACID DERIVATIVE | MANAC INCORPORATED (JP) | 2014-02-20 | — | — | US | claimed |
| EP-2124924-B1 | Active ingredient combination of a retinoid and a hormone combination with contraceptive action as medicament for treatment of skin diseases | GRUENENTHAL GMBH (DE) | 2012-06-27 | — | — | EP | claimed |
| US-20090312296-A1 | ACTIVE INGREDIENT COMBINATION OF A RETINOID AND A HORMONE COMBINATION WITH CONTRACEPTIVE ACTION AS MEDICAMENT FOR TREATMENT OF SKIN DISEASES | GRUNENTHAL GMBH (DE) | 2009-12-17 | — | — | US | claimed |
| EP-2124924-A1 | ACTIVE INGREDIENT COMBINATION OF A RETINOID AND A HORMONE COMBINATION WITH CONTRACEPTIVE ACTION AS MEDICAMENT FOR TREATMENT OF SKIN DISEASES | Grünenthal GmbH (DE) | 2009-12-02 | — | — | EP | claimed |
| WO-2008077541-A1 | ACTIVE INGREDIENT COMBINATION OF A RETINOID AND A HORMONE COMBINATION WITH CONTRACEPTIVE ACTION AS MEDICAMENT FOR TREATMENT OF SKIN DISEASES | Grünenthal GmbH (DE) | 2008-07-03 | — | — | WO | claimed |
| EP-0327263-B1 | Hair growth stimulation with nitroxide and other radicals | PROCTOR PETER H (US) | 1994-09-07 | — | — | EP | claimed |
| WO-1988005653-A1 | TOPICAL COMPOSITION FOR STIMULATING HAIR GROWTH WITH STABLE FREE RADICALS | PROCTOR PETER H (US) | 1988-08-11 | — | — | WO | claimed |
| EP-0002533-B1 | USE OF RETINOIDS AS MEDICINES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1986-06-25 | — | — | EP | claimed |
| US-4215215-A | 9-Phenyl-nonate traene compounds | HOFFMANN-LA ROCHE INC. (US) | 1980-07-29 | — | — | US | claimed |
| US-4105681-A | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1978-08-08 | — | — | US | claimed |
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| CN-116334113-A | Conditionally active heterodimeric polypeptides and methods of use thereof | 加利福尼亚大学董事会 | 2023-06-27 | — | — | CN | disclosed |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| EP-0002533-A2 | Use of retinoids as medicines | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1979-06-27 | — | — | EP | disclosed |
| US-4105681-A | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1978-08-08 | — | — | US | disclosed |
| US-4021574-A | Antidandruff compositions containing 9-(4-lower alkoxy-2,3,6-trilower-alkylphenyl)-3,7-dimethyl-nona-2,4,6,8-tetraen-1-oic acid lower alkyl amides | HOFFMANN-LA ROCHE INC. (US) | 1977-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | RXRA 2611/4885RARG 1312/4885RARA 2373/4885 |
| US-20140051876-A1 | METHOD FOR MANUFACTURING PHOSPHONOCROTONIC ACID DERIVATIVE | C1S, C3AR1, C9 | RXRA 1711/4885RARG 2703/4885RARA 1727/4885 |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | EHMT2, BHMT, SHMT2 | RXRA 2611/4885RARG 1312/4885RARA 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.